FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972275101> ?p ?o ?g. }

• W1972275101 endingPage "1139" @default.
• W1972275101 startingPage "1133" @default.
• W1972275101 abstract "OBJECTIVE To evaluate the efficacy of tolterodine extended‐release (ER) plus tamsulosin on lower urinary tract symptoms (LUTS) as assessed by changes in the International Prostate Symptom Score (IPSS) in men who met symptom entry criteria for both overactive bladder (OAB) and benign prostatic hyperplasia (BPH) trials. PATIENTS AND METHODS Men aged ≥40 years with an IPSS of ≥12 and diary‐documented OAB symptoms (≥8 voids/24 h and ≥3 urgency episodes/24 h, with or without urgency urinary incontinence) who reported at least moderate problems related to their bladder condition were randomized to receive placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER (4 mg) + tamsulosin (0.4 mg) once daily for 12 weeks. Patients completed the IPSS at baseline and at 1, 6 and 12 weeks. RESULTS Patients receiving tolterodine ER + tamsulosin had significantly greater improvements than those taking placebo on IPSS storage subscale scores and scores for all three individual storage items included on the IPSS (urinary frequency, urgency, and nocturnal micturitions) by 12 weeks. Storage subscale and urgency scores were significantly improved vs placebo at 1 and 6 weeks, whereas frequency scores were significantly improved at 6 weeks. Changes in IPSS storage subscale and individual storage item scores in the tolterodine ER and tamsulosin monotherapy groups were not significantly different from placebo at most time points. IPSS voiding subscale scores and scores for three of four individual voiding items (sensation of incomplete emptying, intermittency, and weak stream) were significantly improved by 12 weeks for patients receiving tamsulosin monotherapy vs placebo. Voiding subscale and intermittency scores were significantly improved vs placebo at 1 week; weak stream scores were significantly improved at 1 and 6 weeks. The IPSS voiding subscale and individual voiding item scores in the tolterodine ER + tamsulosin and tolterodine ER groups were not significantly different from placebo at most time points. CONCLUSIONS In this distinct clinical research population of men who met traditional symptom entry criteria for both OAB and BPH trials, tolterodine ER + tamsulosin was significantly more effective than placebo in treating storage LUTS, including OAB symptoms. Tamsulosin monotherapy produced significant improvements in voiding LUTS." @default.
• W1972275101 created "2016-06-24" @default.
• W1972275101 creator A5032546357 @default.
• W1972275101 creator A5038940693 @default.
• W1972275101 creator A5049019006 @default.
• W1972275101 creator A5076037136 @default.
• W1972275101 creator A5081214299 @default.
• W1972275101 creator A5085416965 @default.
• W1972275101 date "2008-10-09" @default.
• W1972275101 modified "2023-10-17" @default.
• W1972275101 title "Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score" @default.
• W1972275101 cites W1514921595 @default.
• W1972275101 cites W1967347194 @default.
• W1972275101 cites W1968860914 @default.
• W1972275101 cites W1969218478 @default.
• W1972275101 cites W2011746657 @default.
• W1972275101 cites W2020443535 @default.
• W1972275101 cites W2022417704 @default.
• W1972275101 cites W2022422644 @default.
• W1972275101 cites W2022805390 @default.
• W1972275101 cites W2028950772 @default.
• W1972275101 cites W2032650666 @default.
• W1972275101 cites W2045828646 @default.
• W1972275101 cites W2055614074 @default.
• W1972275101 cites W2065814656 @default.
• W1972275101 cites W2068543068 @default.
• W1972275101 cites W2078997630 @default.
• W1972275101 cites W2088552272 @default.
• W1972275101 cites W2089437227 @default.
• W1972275101 cites W2105749030 @default.
• W1972275101 cites W2121759271 @default.
• W1972275101 cites W2134121470 @default.
• W1972275101 cites W2136535014 @default.
• W1972275101 cites W2155381616 @default.
• W1972275101 cites W2157421402 @default.
• W1972275101 cites W2993539218 @default.
• W1972275101 cites W4236163484 @default.
• W1972275101 doi "https://doi.org/10.1111/j.1464-410x.2008.07761.x" @default.
• W1972275101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18510659" @default.
• W1972275101 hasPublicationYear "2008" @default.
• W1972275101 type Work @default.
• W1972275101 sameAs 1972275101 @default.
• W1972275101 citedByCount "67" @default.
• W1972275101 countsByYear W19722751012012 @default.
• W1972275101 countsByYear W19722751012013 @default.
• W1972275101 countsByYear W19722751012014 @default.
• W1972275101 countsByYear W19722751012015 @default.
• W1972275101 countsByYear W19722751012016 @default.
• W1972275101 countsByYear W19722751012017 @default.
• W1972275101 countsByYear W19722751012019 @default.
• W1972275101 countsByYear W19722751012020 @default.
• W1972275101 countsByYear W19722751012021 @default.
• W1972275101 countsByYear W19722751012023 @default.
• W1972275101 crossrefType "journal-article" @default.
• W1972275101 hasAuthorship W1972275101A5032546357 @default.
• W1972275101 hasAuthorship W1972275101A5038940693 @default.
• W1972275101 hasAuthorship W1972275101A5049019006 @default.
• W1972275101 hasAuthorship W1972275101A5076037136 @default.
• W1972275101 hasAuthorship W1972275101A5081214299 @default.
• W1972275101 hasAuthorship W1972275101A5085416965 @default.
• W1972275101 hasConcept C121608353 @default.
• W1972275101 hasConcept C126322002 @default.
• W1972275101 hasConcept C126894567 @default.
• W1972275101 hasConcept C142724271 @default.
• W1972275101 hasConcept C204787440 @default.
• W1972275101 hasConcept C27081682 @default.
• W1972275101 hasConcept C2776235491 @default.
• W1972275101 hasConcept C2776547966 @default.
• W1972275101 hasConcept C2777562237 @default.
• W1972275101 hasConcept C2778531004 @default.
• W1972275101 hasConcept C2778941218 @default.
• W1972275101 hasConcept C2779478474 @default.
• W1972275101 hasConcept C2780542891 @default.
• W1972275101 hasConcept C2781020410 @default.
• W1972275101 hasConcept C71924100 @default.
• W1972275101 hasConcept C77411442 @default.
• W1972275101 hasConceptScore W1972275101C121608353 @default.
• W1972275101 hasConceptScore W1972275101C126322002 @default.
• W1972275101 hasConceptScore W1972275101C126894567 @default.
• W1972275101 hasConceptScore W1972275101C142724271 @default.
• W1972275101 hasConceptScore W1972275101C204787440 @default.
• W1972275101 hasConceptScore W1972275101C27081682 @default.
• W1972275101 hasConceptScore W1972275101C2776235491 @default.
• W1972275101 hasConceptScore W1972275101C2776547966 @default.
• W1972275101 hasConceptScore W1972275101C2777562237 @default.
• W1972275101 hasConceptScore W1972275101C2778531004 @default.
• W1972275101 hasConceptScore W1972275101C2778941218 @default.
• W1972275101 hasConceptScore W1972275101C2779478474 @default.
• W1972275101 hasConceptScore W1972275101C2780542891 @default.
• W1972275101 hasConceptScore W1972275101C2781020410 @default.
• W1972275101 hasConceptScore W1972275101C71924100 @default.
• W1972275101 hasConceptScore W1972275101C77411442 @default.
• W1972275101 hasIssue "9" @default.
• W1972275101 hasLocation W19722751011 @default.
• W1972275101 hasLocation W19722751012 @default.
• W1972275101 hasOpenAccess W1972275101 @default.
• W1972275101 hasPrimaryLocation W19722751011 @default.
• W1972275101 hasRelatedWork W1949541203 @default.

• next